We report the fatty acid composition of mother's own human milk from one of the largest US cohorts of lactating mothers of preterm infants. Milk fatty acid data were used as a proxy for intake at enrollment in infants (n ¼ 150) who received human milk with a powder human milk fortifier (HMF; Control) or liquid HMF [LHMF; provided additional 12 mg docosahexaenoic acid (DHA), 20 mg arachidonic acid (ARA)/ 100 mL human milk]. Mothers provided milk samples (n ¼ 129) and reported maternal DHA consumption (n ¼128). Infant blood samples were drawn at study completion (Study Day 28). Human milk and infant PPL fatty acids were analyzed using capillary column gas chromatography.
Introduction
Human milk is considered the preferred source of infant nutrition. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommends the addition of supplemental nutrients to human milk to meet preterm infant requirements [1] . Supplementation of human milk with human milk fortifier (HMF) provides calories as well as macro-and micronutrients at levels approximating estimated preterm infant needs [2] . Infants born prematurely have low total body long chain polyunsaturated fatty acid (LCPUFA) stores [3, 4] and the docosahexaenoic acid (DHA) and arachidonic acid (ARA) content of preterm human milk may be insufficient to meet increased needs. Therefore the current ESPGHAN standard for preterm infants also recommends fortification of mother's own human milk as necessary to meet high LCPUFA requirements (11-27 mg DHA/100 kcal and 16-39 mg ARA/100 kcal) or use of infant formulas designed for premature infants [1] . Preterm infant DHA and ARA status rapidly declines [5, 6] and low whole blood DHA and/or ARA are associated with poor clinical outcomes, such as increased risk of chronic lung disease and late-onset sepsis [6] . Consequently, postnatal delivery of dietary LCPUFAs in the recommended range represents a challenge for those caring for infants receiving human milk or formula.
Preterm formulas have been developed based on worldwide human milk DHA and ARA data in order to provide standardized fortification [7] . Human milk long chain n-3 and n-6 fatty acids can vary at both population and individual levels and depend particularly on maternal dietary pattern and habits [7] [8] [9] [10] [11] [12] . For example, analysis of dietary fatty acid intake and plasma n-3 and n-6 fatty acids from pregnant Canadian women demonstrated that dietary DHA intakes in some women during the third trimester were below that necessary for DHA accretion in both fetal and maternal tissues [13] . Western diets with low intake of n-3-rich fish are also reflected in lower maternal blood DHA [7, 9] . Human milk ARA concentrations are typically higher, but less variable, than DHA [7] . Consequently, clinical trials of preterm formulas providing 17 mg DHA and 34 mg ARA per 100 kcal as fed (approximately 0.33% and 0.66% of total fatty acids, respectively, for formulas with 5.1 g total fat/100 kcal formula) have demonstrated improved growth and development compared with similar formulas with no LCPUFAs [14, 15] .
Given the increased likelihood for suboptimal DHA and ARA status and risk for the associated negative consequences in premature infants, DHA and ARA in a commercially sterile liquid HMF (LHMF; Enfamil  s Mead Johnson Nutrition, Evansville, IN) were targeted, when added to "typical" US human milk, to be similar to the levels studied in preterm formulas. Appropriate absorption of preformed DHA and ARA added in preterm infant formula, as measured by metabolic balance studies [16] and from fortified human milk, as measured by increases in blood levels [17] has been previously demonstrated with no evidence that fortifying human milk with these fatty acids negatively affects availability from human milk. We recently demonstrated that fortification with LHMF, formulated to increase the DHA, ARA, total fat, and protein content of human milk, significantly improved preterm infant growth when compared to milk fortified using a powder HMF without DHA or ARA (Control, Mead Johnson Nutrition) [18] . As part of that study, we collected mother's own preterm milk to provide baseline information on unfortified milk and infant plasma samples to examine how dietary provision of a standardized level of DHA and ARA affects preterm infant status. Here we report on the fatty acid composition of preterm human milk from this large US cohort of lactating mothers, as well as LCPUFAs in plasma phospholipids of their infants.
Methods
Participants in this study (150 premature infants and their mothers) were recruited for a double-blind, randomized, controlled, prospective study to evaluate growth, tolerance and safety of a new ultra-concentrated LHMF [18] . Briefly, at enrollment the infants were r 30 3/7 weeks gestational age with birth weights r1250 g, exclusively fed unfortified human milk (mother's own or donor milk) with enteral intake of Z 80 mL/kg per day, and had no congenital malformations or underlying disease likely to interfere with growth or tolerance of fortified milk. For 28 days, or until hospital discharge or discontinuation of breast milk feedings, infants received human milk (mother's own or donor milk) supplemented with either a powder HMF (Control) or the LHMF beginning at half strength on Study Day 1 and full strength thereafter. The study was conducted at 14 sites from 7 states (Florida, Nebraska, North Carolina, Illinois, Arkansas, New York, and Virginia). A parent or guardian of each infant provided written informed consent. Institutional review boards at each study site reviewed and approved the study protocol. Medically-confirmed serious adverse events were monitored and documented throughout the study. At study enrollment, data on infant birth characteristics were collected [18] . In addition, mothers were asked if they regularly (Z1 time per week) consumed any fish and/or DHA supplements during the last 12 weeks of pregnancy. Responses were recorded as "yes" or "no."
Study fortifiers
Preterm human milk fortified with LHMF provides $ 20% more protein and almost double the amount of DHA and ARA when compared with preterm milk fortified with Control HMF. The ranges for DHA and ARA levels naturally observed in human milk support the nutritional acceptability and safety of ranges for the calculated levels of DHA and ARA the LHMF was formulated to provide as well as their estimated ratio in human milk fortified with LHMF. For example, adding LHMF to milk corresponding to the lowest mean US values (0.15% DHA and 0.4% ARA [7] ) would increase levels in fortified milk to approximately 0.29% DHA and 0.57% ARA (or 18 mg DHA and 35 mg ARA per 100 kcal; assuming total fat of 3.5 g/100 mL in unfortified preterm human milk and 6.1 g/100 kcal in milk fortified with LHMF). Addition of LHMF to human milk with as much as 1% DHA and/or ARA would lower the level of the LCPUFAs as a percent of total fat (to 0.8% DHA and 0.94% ARA) in fortified human milk. Using the reported values for worldwide means for DHA and ARA, Table 1 shows the calculated macronutrient and polyunsaturated fatty acid (PUFA) estimates for content of preterm milk fortified with study fortifiers at full strength.
Fatty acid analysis
A single milk sample (1-2 ml) was collected from each mother no earlier than postpartum day 6. The samples were collected after the "let down" reflex occurred or following a complete expression of milk to ensure a homogeneous sample. On Study Day 28, blood samples (1 ml) were obtained from the infants and plasma separated from RBCs by centrifugation. Milk and infant plasma samples were frozen at À20 1C and shipped on dry ice to the Retina Foundation of the Southwest (Dallas, TX) for fatty acid analysis. Lipids were extracted, total phospholipids isolated, and fatty acid methyl esters analyzed by capillary column gas chromatography as previously described [19] . Fatty acids in milk and infant plasma phospholipids (PPLs) were expressed as weight percent of total fatty acids. No donor milk was analyzed.
Sample size determination and statistical methods
A sample size of 50 infants per study group was originally determined adequate to detect group differences in growth [18] . Fisher's exact test was used to analyze maternal consumption of fish and/or use of DHA supplements during the last 12 weeks of pregnancy. The Kruskal-Wallis test was used to analyze the fatty acid content of breast milk and infant plasma phospholipids. Infant plasma fatty acid analyses were conducted for two data sets. A primary analysis included data from all infants who had a blood sample drawn no more than 3 days after the last feeding of human milk fortified with study HMF. A secondary analysis was based on a subset of infants included in the primary analysis who met the following additional criteria (per-protocol efficacy analysis): received Z80% of their energy intake from fortified human milk for at least the first two weeks of the study and were NPO (nil per os) for no more than 2 days during this period, consumed study fortifier at full strength on Study Day 3, received no glucocorticoid therapy during the full 28 day study, and had no disease or illness that affected growth. a None added; contribution from human milk only. Powder HMF does not include DHA or ARA; Human milk levels calculated using published mean values of 0.32% of total fatty acids for DHA and 0.47% of total fatty acids for ARA [7] . LHMF provides 12 mg DHA and 20 mg ARA when added to 100 ml (66 kcal) human milk.
Results

Study population
As previously reported, between October 2008 and July 2010, 150 premature infants were enrolled and randomized [18] . Briefly, a total of 146 enrolled infants consumed some study fortifier (LHMF: 74; Control: 72) and 106 infants completed the full 28 day study (LHMF: 51, 65%; Control: 55, 76%). Infant birth characteristics including anthropometrics (weight, length, head circumference), gestational age, gender, APGAR score, race, ethnicity, delivery type (vaginal vs cesarean section) and birth type (singleton or twin) as well as study completion rates did not differ between groups [18] . The use of donor milk occurred at two study sites. There were no group differences in the percentage of infants who consumed donor milk (LHMF: 14, 19%; Control: 18, 25%; P ¼0.427).
Human milk fatty acid composition
Of the 150 initially enrolled, 129 mothers (64 with infants in the LHMF and 65 in the Control group) provided a single, unfortified human milk sample for fatty acid analysis (Fig. 1) differences in monounsaturated fatty acids were detected. Within the n-3 PUFA measured, docosapentaenoic acid (DPAn-3; 22:5n-3) was significantly lower for the LHMF compared to the Control group (by primary and secondary analysis) and DHA was significantly higher for the LHMF compared to the Control group (by primary and secondary analysis). No significant differences in other n-3 PUFAs, including ALA and eicosapentaenoic acid (EPA; 20:5n-3), were detected. Within the n-6 PUFA measured, 20:2n-6 (by secondary analysis only), LA and dihomo-γ-linolenic acid (DGLA; 20:3n-6) (by primary and secondary analysis) were significantly lower for the LHMF compared to the Control group, and ARA was significantly higher for the LHMF compared to the Control group (by primary and secondary analysis).
Maternal consumption of DHA and infant PPL DHA status at Study Day 28
Of the 129 mothers who provided human milk samples for fatty acid analysis, 128 reported on maternal DHA consumption: 76 (59.4%) reported consuming no fish or DHA supplements (DHA À; Fig. 1 ) during the last 12 weeks of pregnancy, whereas 52 (40.6%) reported consuming DHA (DHA þ ; further categorized by supplements only: 25, 19.5%; fish only: 16, 12.5%; or both supplements and fish: 11, 8.6%). When analyzed by infant study group, there was no statistical difference between numbers of mothers by DHA À (LHMF: 36, 57.1%; Control: 40, 61.5%) or DHA þ (LHMF: 27, 42.9%; Control: 25, 38.5%) group. However, mean (7 SD) human milk DHA (as a percentage of total fatty acids) was 48% higher among mothers in the DHAþ (0.34 70.21%) than the DHA-group (0.23 70.12%).
These data prompted our exploratory examination of how the effects of maternal consumption of fish and/or DHA supplements interfaced with infant DHA status at Study Day 28 among infants who adhered most closely to the study protocol (Fig. 2) . Using maternal DHA consumption data that corresponded to infants within the PPL DHA secondary analysis (per-protocol efficacy), PPL DHA content was highest for infants in the LHMF group whose mothers reported regular consumption of DHA supplements and/ or fish (LHMF/DHAþ : 3.82 70.89%). Infant PPL DHA content was lowest for infants in the Control group whose mothers reported no regular ( o1 time per week) consumption of DHA supplements or fish (Control/DHAÀ : 3.05 70.42%). The study was not powered to provide statistical analysis for these post-hoc sub-groups. However, we wanted to provide this preliminary information as a starting point for subsequent examination of the real-world intersection of maternal DHA supplementation and infant LCPUFA intake.
Discussion
This study surveyed the fatty acid composition of human milk from one of the largest cohorts of lactating mothers of preterm infants in the US to date, with samples representing 14 study centers in 7 states. As expected, there were no significant group differences between LHMF and Control study participants' mothers in unfortified, expressed human milk fatty acids, including DHA and ARA, except for small differences noted in 16:0 and 22:1. DHA as a percentage of total fatty acids (median values) was 0.25% (IQR, 0.19-0.31%) for the LHMF and 0.23% (0.17-0.31%) for the Control group; ARA was 0.60% (0.50-0.68%) for the LHMF and 0.62% (0.54-0.70%) for the Control group. Results from this study are near the upper mean levels of DHA and ARA reported for US term human milk [7] and consistent with levels analyzed in a systematic review of reported preterm milk values [20] . Mother's own preterm milk fatty acid data were used as a proxy for infant intake at enrollment to assess the adequacy of standardized DHA and ARA fortification provided in a commercially sterile liquid HMF. In the current analysis, we demonstrated PPL DHA and ARA were significantly higher in infants who received human milk fortified with LHMF (providing an additional 12 mg DHA and 20 mg ARA per 100 mL human milk) when compared to the powder Control HMF that provided no DHA or ARA. Consequently, when provided in human milk, particularly milk low in LCPUFAs, the improved liquid HMF enriched with DHA and ARA helps meet the ESPGHAN recommendation for DHA and ARA fortification.
Given the relatively short dietary intervention in our study, measurement of LCPUFAs in plasma PL, rather than red blood cell PL, was more likely to demonstrate significant changes due to dietary LCPUFAs, as noted previously [21] . On Study Day 28, PPL DHA and ARA levels were significantly higher for infants in the LHMF compared to the Control group (primary and secondary analysis). Infant PPL DHA and ARA in the current study were also comparable to those recently reported for preterm infants who received DHA provided via maternal supplementation, human milk, or in infant formulas. For example, plasma DHA as percent of total fatty acids increased significantly (P¼ 0.009) by $ 2-fold after 7 weeks of intervention in preterm Canadian infants whose mothers received dietary DHA supplementation beginning within the first week postpartum compared to unsupplemented mothers [22] . Preterm Australian infants received human milk (from their mothers who had been supplemented with DHA or placebo for resultant mean milk levels of 0.85% or 0.25% DHA) and/or formula with 1.0% (High) or 0.33% (Standard) DHA from at least day 4 of life until the expected date of delivery (median duration of feeding, 9.4 weeks) [23] . Reported means (7SD) for PPL DHA were 5.32 70.94% (High) and 3.89 70.67% (Standard) and for PPL ARA were 10.25 71.19% (High) and 11.16 71.50% (Standard) by the end of feeding [24] . German preterm infants enrolled within the first 14 days of life received either human milk or one of three formulas with ARA at 0.1% and DHA at 0.04% (low), 0.33% (medium), or 0.52% (high) over a 28 day period [21] . Increases in PPL DHA at day 28 were dose-dependent in formula-fed infants; medians reported for PPL DHA were 3.46% in the human milk group and 2.15% (low), 3.41% (medium), and 4.20% (high) in formula groups.
In the current study, PPL LA was statistically higher in the Control group (primary and secondary analysis) but differences were small and not considered clinically significant. Medians ( $ 21 to 23%) were similar to those reported for LA in Australian infants for the High (21.72%) and Standard (20.51%) DHA groups. Higher dietary LA intake is normally reflected in higher plasma and red blood cell levels. In mothers from the current study, median values for human milk LA as a percentage of total fatty acids were slightly higher (16.75%) than those reported previously for US human milk (14.78%) [12] ; therefore, higher infant levels of PPL LA would be expected. Infant PPL DPAn-3 and DGLA were also statistically lower in the LHMF versus Control group (primary and secondary analysis), although all values were consistent with aforementioned levels reported for preterm German infants. [21] That study evaluated the effect of increasing DHA content of formulas (0.04% to 0.33% to 0.52%) on LCPUFA synthesis using stable-isotope labeled LA and ALA, and found that increasing DHA did not inhibit ARA or DHA synthesis. A significant reduction in DPAn-3 production associated with increased PPL DHA was also reported, in line with our results demonstrating lower DPAn-3 in the LHMF group. Similarly, an earlier study in adults reported a reduction of DGLA synthesis with dietary ARA of 1.7 vs 0.21 g/day [25] .
Our study also allowed examination of liquid HMF use within a real-world neonatal ICU population in which approximately 75% of study participants received fortified mother's own preterm human milk. Because of the known benefits of feeding human milk, donor milk is offered with increased frequency in the NICU as a viable alternative to mother's own milk [26] . However, the DHA content of pooled US donor milk is typically lower when compared to mother's own milk or formula and may not meet guidelines for recommended provision of LCPUFAs to infants [3, 27] . For example, ARA levels ranged from 0.40% to 0.46% and DHA levels ranged from 0.073% to 0.20% in pooled samples from milk banks in Texas, North Carolina, California, and Iowa [28] and the DHA level from one Ohio milk bank was reported at $ 0.1% [29] . In addition, systematic review of fatty acid composition of human milk from mothers of term versus preterm infants indicated higher DHA levels in the latter, suggesting a significant benefit in feeding milk of a matched lactational age to premature infants [20] . The current data support the ESPGHAN-recommended use of mother's own milk of matched lactational age and fortification with the liquid HMF to approximate the DHA and ARA levels appropriate for a term infant.
It is well-established that maternal dietary DHA supplementation raises human milk DHA levels. This was evaluated in the current study using self-reported consumption of fish and/or DHA supplements (Z1 time per week during the last 12 weeks of pregnancy), providing a rough estimate of maternal DHA intake. This simple indicator demonstrated higher mean DHA in human milk among mothers with use of dietary DHA sources versus those without. As noted, although the study was not powered to analyze post-hoc descriptive sub-group data with statistical strength, PPL DHA was highest for infants with mothers who routinely consumed DHA from fish and/or supplements prenatally who were also randomized to receive LHMF. Over half of mothers who provided milk samples consumed no supplemental or significant dietary source of DHA late in gestation, suggesting poor compliance with expert recommendations of at least 200 mg/day dietary DHA [27] . The human milk data in the current study demonstrate the continued need to explore and encourage increased maternal DHA intake or supplementation in US women.
Overall, this study provided much-needed data on fatty acid composition of preterm mother's own human milk from a large US cohort of lactating mothers, representing an essential regional cross-section. Given the importance of DHA and ARA for preterm infant growth and development [14, 15] , and emerging evidence that even higher levels of DHA may provide additional benefits [17, 23] , it is important to assure that preterm infants fed fortified human milk also receive, at minimum, the levels of DHA and ARA found in premature formulas. To this end, adding the improved, commercially sterile liquid HMF to human milk significantly increased the preterm milk content of DHA and ARA to levels within the expert-recommended range and improved the DHA and ARA status of preterm infants. Results from our simple dietary survey also demonstrate the need to improve US human milk DHA status through increased maternal dietary supplementation at expert-recommended levels.
